Medtelligence: Linking Science to Clinical Practice - Medtelligence

Medtelligence Hero

Linking Science
to Clinical Practice

Innovative, high-quality medical education for clinicians in cardiology and other specialties.

Featured

Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CE
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP; Ankana Daga, MD
0.25 credits
- Richard Lafayette, MD, FACP
- Ankana Daga, MD
0.25 credits
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD; Gil Yosipovitch, MD
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
MinuteCE®
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS; Michael Nassif, MD, MSc
1.00 credit 7 episodes
- Ahmad Masri, MD, MS
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 credit 7 episodes
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CE
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD; Muh Geot Wong, MBBS, PhD
0.25 credits
- An De Vriese, MD, PhD
- Muh Geot Wong, MBBS, PhD
0.25 credits

Popular

NEW EPISODE
Safety in oHCM Therapy: How and When to Transition Treatment?
Safety in oHCM Therapy: How and When to Transition Treatment?
MinuteCE®
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
1.00 program credit
- Anjali Owens, MD
1.00 program credit
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Nephrology
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
- Brendon Neuen, MBBS, PhD
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CE
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP; Claudia Seikrit, MD
0.25 credits
- Chee Kay Cheung, MBChB, PhD, FRCP
- Claudia Seikrit, MD
0.25 credits
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CE
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD; Gil Yosipovitch, MD
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc; Anjali Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
0.25 credits
- Jonathan Barratt, MD, PhD
0.25 credits